TABLE 3.
Clinical information of neurologically evaluated HIV cohort (ARBRE study)
| Parameter | Early cART (n = 9)a | Later cART (n = 10)a |
|---|---|---|
| Age, yrs | 33 (22–60) | 33 (20–48) |
| Male, n (%) | 9 (100) | 10 (100) |
| Route of transmission, MSMb, n (%) | 9 (100) | 10 (100) |
| Estimated days since infection to cART | 70 (12–81) | 360 (180–660) |
| Integrase strand transfer inhibitor (INSTI), n (%) | ||
| Raltegravir | 2 (22.2) | 1 (10) |
| Elvitegravir | 4 (44.4) | 3 (30) |
| Dolutegravir | 3 (33.3) | 6 (60) |
| Plasma viral load Log10c | 5.3 (3.6–6.7) | 4.2 (2–5) |
| CD4 cell countd | 630 (165–854) | 554 (238–936) |
| CD8 cell countd | 844 (391–1,534) | 907 (473–3,662) |
| CD4/CD8 ratio | 0.6 (0.2–1.6) | 0.6 (0.2–0.9) |
| SIRT2 ELISA (n)e | 9 | 10 |
| Cognitive test evaluation (n) | 9 | 9 |
| Brain neuroimage assessment (n) | 9 | 8 |
a
Values expressed as median with range.
b
MSM, men who have sex with men.
c
Plasma viral load determined on the day of cART initiation.
d
CD4 and CD8 counts are indicated as cells/mm3.
e
n, number of individuals tested by ELISA, cognitive evaluations, and neurological image assessments.